Geron's Clinical Trial: Risk, Front-loading and Costs
The Vatican doesn't particularly care for the idea. "Unacceptable" was the word it used.
Over at Bioworld Today, it was "the dawn of a new era."
A reader of the New York Times warned of the danger of "front-loaded" arguments that can be detrimental to stem cell research.
What they were talking about is Geron and its re-vitalized clinical trial of an hESC…
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.